---
title: "Saroglitazar in Primary biliary cholangitis: References"
description: "Reference list for the formulary evidence report on Saroglitazar in Primary biliary cholangitis. 79 cited documents."
canonical: "https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Saroglitazar in Primary biliary cholangitis: References

<a id="references"></a>

## 5 References

1. [AASLD (2018)](https://www.aasld.org/sites/default/files/2022-04/PracticeGuidelines-PBC-November2018_1.pdf)
2. [AASLD (2021)](https://pubmed.ncbi.nlm.nih.gov/34431119/)
3. [Aghemo et al. (2026)](https://www.sciencedirect.com/science/article/pii/S1590865826007851)
4. [Alvaro et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70118)
5. [ClinicalTrials.gov NCT03112681](https://clinicaltrials.gov/study/NCT03112681)
6. [ClinicalTrials.gov NCT05133336](https://clinicaltrials.gov/study/NCT05133336)
7. [ClinicalTrials.gov NCT06427395](https://clinicaltrials.gov/study/NCT06427395)
8. [ClinicalTrials.gov NCT07216235](https://clinicaltrials.gov/study/NCT07216235)
9. [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)
10. [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)
11. [EASL Congress (2026)](https://www.easlcongress.eu/wp-content/uploads/2026/05/Media-Release_scientific-2026_28-May_none-1.pdf)
12. [EASL-AASLD (2026)](https://pubmed.ncbi.nlm.nih.gov/42191456/)
13. [Elman et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2875190/)
14. [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)
15. [FDA (2025)](https://www.govinfo.gov/content/pkg/FR-2025-11-24/pdf/2025-20767.pdf)
16. [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)
17. [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819)
18. [Gelhorn et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12315290/)
19. [Gerussi et al. (2021)](https://www.sciencedirect.com/science/article/abs/pii/S159086582030387X)
20. [Giannini et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.16222)
21. [Giri et al. (2019)](https://www.sciencedirect.com/science/article/abs/pii/S0928098719300132)
22. [Gish et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/lci2.70044)
23. [GSK (2026)](https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda/)
24. [Hirschfield et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38381664/)
25. [Indiana University](https://research-studies.allinforhealth.info/us/en/listing/14117/a-double-blind-placebo-controlled-randomized-NCT07424677-774/)
26. [Intercept Pharmaceuticals (2025)](https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html)
27. [Jain et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4492752/)
28. [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)
29. [Kanth et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573520/)
30. [Kowdley et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37962077/)
31. [Kumar et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12909387/)
32. [Kumar et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556923/)
33. [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)
34. [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)
35. [Levy et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11999412/)
36. [Levy et al. (2025b)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-5/assessing-the-relationship-between-pruritus-and-work-productivity-among-individuals-with-pbc-and-pruritus-results-from-the-itch-e-study)
37. [Levy et al. (2025c)](https://onlinelibrary.wiley.com/doi/full/10.1111/liv.70276)
38. [Lin et al. (2024)](https://link.springer.com/article/10.1186/s13643-024-02460-0)
39. [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)
40. [Liver International (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70400)
41. [Martins et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41869905/)
42. [Martins et al. (2026b)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-1-4/beyond-the-health-sector-estimating-the-societal-and-fiscal-impact-of-primary-biliary-cholangitis-in-the-united-states)
43. [Mayo et al. (2023)](https://link.springer.com/article/10.1007/s10620-022-07581-x)
44. [MedChemExpress](https://file.medchemexpress.com/batch_PDF/HY-19937A/Saroglitazar-magnesium-SDS-MedChemExpress.pdf)
45. [National Institute of Diabetes and Digestive and Kidney Diseases (2021)](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/treatment)
46. [National Institute of Diabetes and Digestive and Kidney Diseases definition and facts page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/definition-facts)
47. [National Institute of Diabetes and Digestive and Kidney Diseases symptoms and causes page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/symptoms-causes)
48. [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)
49. [Patel et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29224415/)
50. [Poey (2026)](https://doi.org/10.2139/ssrn.6968638)
51. [Saeedian et al. (2025)](https://link.springer.com/article/10.1186/s12876-025-03821-2)
52. [Schattenberg et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1111/apt.70598)
53. [Shamseddine et al. (2026)](https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-of-patients-with-primary-biliary-cholangitis-in-the-united-states/)
54. [Sohal et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42101777/)
55. [Tang et al. (2024)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1432814/full)
56. [Veeva Systems EPICS-III study page](https://ctv.veeva.com/study/saroglitazar-magnesium-for-treatment-of-primary-biliary-cholangitis)
57. [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)
58. [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)
59. [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)
60. [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)
61. [Vuppalanchi et al. (2020)](https://assets.website-files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late-breaking%20Abstracts-%20Oct%2030.pdf)
62. [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)
63. [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)
64. [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)
65. [Vuppalanchi et al. (2026)](https://www.researchgate.net/publication/405332836_LBO-001_A_phase_2b3_trial_of_saroglitazar_in_primary_biliary_cholangitis_EPICS_III)
66. [You et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10037524/)
67. [Zhao et al. (2026)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1859342/full)
68. [Zydus Lifesciences (2020)](https://www.zyduslife.com/public/pdf/pressrelease/Zydus_granted_Fast_Track_Designation_by_the_USFDA_for_Saroglitazar_in_the_treatment_of_patients_with_PBC.pdf)
69. [Zydus Lifesciences (2024)](https://zyduslife.com/investor/admin/uploads/21/83/Zydus-Announces-Completion-of-Enrolment-for-EPICS-IIITM-Phase-2b-3-trial-evaluating-Saroglitazar-Mg-in-treatment-of-Primary-Biliary-Cholangitis.pdf)
70. [Zydus Lifesciences 19 May earnings call transcript (2026)](https://zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-19-May-26.pdf)
71. [Zydus Lifesciences 4 November earnings call transcript (2026)](https://zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-04-Nov-26.pdf)
72. [Zydus Lifesciences EVIDENCES-X topline results announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Zydus-Announces-Positive-Topline-Results-from-Completed-EVIDENCES-X-Phase-II%28b%29-Clinical-Trial-of-Saroglitazar-Mg-in-MASH.pdf)
73. [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)
74. [Zydus Therapeutics (2025)](https://www.prnewswire.com/news-releases/zydus-therapeutics-reports-positive-topline-results-from-epics-iii-phase-2b3-trial-of-saroglitazar-magnesium-in-patients-with-primary-biliary-cholangitis-302542014.html)
75. [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)
76. [Zydus Therapeutics about us page](https://zydustx.com/about-us/)
77. [Zydus Therapeutics expanded access and compassionate use policy](https://zydustx.com/helping-patients/expanded-access-and-compassionate-use-policy/)
78. [Zydus Therapeutics PBC clinical trials page](https://zydustx.com/clinical-trials/pbc-clinical-trials/)
79. [Zydus Therapeutics pipeline page](https://zydustx.com/pipeline/)

## Related pages
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis.md)
- [Saroglitazar in Primary biliary cholangitis: Terms and abbreviations](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations.md)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary.md)
- [Saroglitazar in Primary biliary cholangitis: Product information and disease description](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description.md)
- [Saroglitazar in Primary biliary cholangitis: Clinical evidence](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence.md)
- [Saroglitazar in Primary biliary cholangitis: Economic information and modeling report](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics.md)
- [Saroglitazar in Primary biliary cholangitis: prevalence by geography](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence.md)
- [Saroglitazar in Primary biliary cholangitis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses.md)
